Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
shop dildos - is great for every girl.
Popular Articles

Migraine And Increased Risk Of Cardiovascular Disease: Migraine Frequency Plays A Role
Women who have migraines with aura may be more likely to have a stroke or heart attack than women who don"t have the condition, and the association varies by migraine frequency, according to research published in the June 24, 2009, online issue of Neurology®, the medical journal of the American Academy of Neurology. An aura is a visual or other sensory disturbance that occurs before the migraine starts, such as seeing bright lights.
drugs without prescription
Independence Blue Cross Expands Its Preventive Health Efforts With Focus On Heart Disease And Diabetes
Prevention is receiving more attention nationwide as a successful strategy to improve the quality and lower the cost of health care. According to the Center for Disease Control and Prevention, care for chronic conditions such as obesity, diabetes, and heart disease account for 75 percent of medical care costs in the United States. Independence Blue Cross (IBC) launched two new programs in June to help members avoid, or better manage, two serious chronic conditions -- heart disease and diabetes.
News of the day
European Medicines Agency Recommends Withdrawal Of Dextropropoxyphene-containing Medicines
Finalising a review of the safety and efficacy of
Mental Health

Seattle Genetics Initiates Phase II Trial Of SGN-35 For Anaplastic Large Cell Lymphoma

Seattle Genetics, Inc. (NASDAQ:SGEN), announced that it has initiated a phase II clinical trial of SGN-35 for patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). SGN-35 is an antibody-drug conjugate (ADC) that utilizes Seattle Genetics" proprietary technology to empower antibodies by linking them to potent cell-killing drugs. "We have observed promising activity in ALCL patients in our phase I trials, notably six out of seven patients treated with SGN-35 have achieved a complete response," said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. "SGN-35 could become an important therapeutic option for patients who relapse or fail to respond to the standard front-line chemotherapy regimen, and we believe that systemic ALCL may offer an additional registration pathway for SGN-35." The single-arm phase II trial will assess efficacy and safety of single-agent SGN-35 in 55 patients with relapsed or refractory systemic ALCL. Patients will receive 1.8 milligrams per kilogram of SGN-35 every three weeks. The primary endpoint of the trial will be objective response rate determined by an independent review facility. Secondary endpoints include duration of response, progression-free survival, overall survival and tolerability. The company plans to enroll patients at more than 30 sites in the U.S., Canada and Europe. Seattle Genetics is also conducting a pivotal trial of SGN-35 for Hodgkin lymphoma under a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA). Data from two phase I trials of SGN-35 were reported in June at the American Society of Clinical Oncology annual meeting and the 14th Congress of the European Hematology Association. In both phase I trials, relapsed or refractory Hodgkin lymphoma and systemic ALCL patients treated with single-agent SGN-35 achieved multiple objective responses at generally well-tolerated doses. The majority of adverse events were Grade 1 and 2, with the most common being fatigue, fever, peripheral neuropathy, diarrhea and nausea. SGN-35 is an ADC comprising an anti-CD30 antibody attached by an enzyme cleavable linker to a potent, synthetic drug payload, monomethyl auristatin E (MMAE), using Seattle Genetics" proprietary technology. The ADC is designed to be stable in the bloodstream, but to release MMAE upon internalization into CD30-expressing tumor cells, resulting in targeted cell-killing. About Systemic Anaplastic Large Cell Lymphoma (ALCL) Lymphoma is a general term for a group of cancers that originate in the lymphatic system. There are two major categories of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma. Systemic ALCL is a type of T-cell non-Hodgkin lymphoma that expresses the CD30 antigen. Although standard front-line combination chemotherapy regimens used to treat systemic ALCL often result in long-term remissions and cures, there are limited therapeutic options and a strong unmet medical need for patients with relapsed or refractory disease. SGN-35 has received orphan drug designation for ALCL from both the FDA and the European Medicines Agency. Seattle Genetics


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009